CRASH-2
2010
Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage
In 20,211 trauma patients with significant haemorrhage, tranexamic acid within 3 hours reduced all-cause death versus placebo.
Result
Efficacy: In-hospital all-cause mortality at 4 weeksRR 0.91 · P = 0.0035
Below 1 favours tranexamic acid within 3 hours, above 1 favours placebo.
- Absolute difference
- 1.5 points
- NNT
- 67
Absolute difference and NNT are derived from the event rates.
Also reported: Benefit only ≤3 h from injury.
- Subtopic
- Tranexamic acid
- Design
- International RCT
- Relevance
- Practice-defining: a trial the guidelines cite as evidence.
- Cited in
- ERC 2025 Resuscitation
- Also listed in
- Trauma & major haemorrhage
- Source
- CRASH-2 Trial Collaborators. Lancet. 2010;376(9734):23-32.doi 10.1016/S0140-6736(10)60835-5
Discussion & critique
Cheap, available, time-critical; the central trauma drug since 2010.